Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Guranda Chitadze, Anna Laqua, Marcus Lettau, Claudia D Baldus & Monika Brüggemann. (2020) Bispecific antibodies in acute lymphoblastic leukemia therapy. Expert Review of Hematology 13:11, pages 1211-1233.
Read now
Read now
Brenda Crowe, Andreas Brueckner, Charles Beasley & Pandurang Kulkarni. (2013) Current Practices, Challenges, and Statistical Issues With Product Safety Labeling. Statistics in Biopharmaceutical Research 5:3, pages 180-193.
Read now
Read now
Wenfeng Chen, Naiqing Zhao, Guoyou Qin & Jie Chen. (2013) A Bayesian Group Sequential Approach to Safety Signal Detection. Journal of Biopharmaceutical Statistics 23:1, pages 213-230.
Read now
Read now
Articles from other publishers (31)
Elsa Coz, Mathieu Fauvernier & Delphine Maucort-Boulch. (2023) An Overview of Regression Models for Adverse Events Analysis. Drug Safety.
Crossref
Crossref
Carey Meredith Suehs, Isabelle Vachier, David Galeazzi, François Vaast, Fanny Cardon, Nicolas Molinari & Arnaud Bourdin. (2023) Standard patient training versus Vik-Asthme chatbot-guided training: ‘AsthmaTrain’ – a protocol for a randomised controlled trial for patients with asthma. BMJ Open 13:2, pages e067039.
Crossref
Crossref
Riaz Qureshi, Xiwei Chen, Carsten Goerg, Evan Mayo-Wilson, Stephanie Dickinson, Lilian Golzarri-Arroyo, Hwanhee Hong, Rachel Phillips, Victoria Cornelius, Mara McAdams DeMarco, Eliseo Guallar & Tianjing Li. (2022) Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials. Epidemiologic Reviews 44:1, pages 55-66.
Crossref
Crossref
Noel Patson, Mavuto Mukaka, Lawrence Kazembe, Marinus J. C. Eijkemans, Don Mathanga, Miriam K. Laufer & Tobias Chirwa. (2022) Comparison of statistical methods for the analysis of recurrent adverse events in the presence of non-proportional hazards and unobserved heterogeneity: a simulation study. BMC Medical Research Methodology 22:1.
Crossref
Crossref
Jessica Roydhouse, Lysbeth Floden, Sabine Braat, Anneke Grobler, Slavica Kochovska, David C Currow & Melanie L Bell. (2022) Missing data in palliative care research: estimands and estimators. BMJ Supportive & Palliative Care 12:4, pages 464-470.
Crossref
Crossref
Cindra Tri Yuniar, Bhekti Pratiwi, Ardika Fajrul Ihsan, Bambang Tri Laksono, Iffa Risfayanti, Annisa Fathadina, Yeonseon Jeong & Eunyoung Kim. (2022) Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. Vaccines 10:2, pages 313.
Crossref
Crossref
Noel Patson, Mavuto Mukaka, Umberto D’Alessandro, Gertrude Chapotera, Victor Mwapasa, Don Mathanga, Lawrence Kazembe, Miriam K. Laufer & Tobias Chirwa. (2021) Joint modelling of multivariate longitudinal clinical laboratory safety outcomes, concomitant medication and clinical adverse events: application to artemisinin-based treatment during pregnancy clinical trial. BMC Medical Research Methodology 21:1.
Crossref
Crossref
Raymond Carragher & Chris Robertson. (2021) Assessing safety at the end of clinical trials using system organ classes: A case and comparative study. Pharmaceutical Statistics 20:6, pages 1278-1287.
Crossref
Crossref
Regina Stegherr, Claudia Schmoor, Michael Lübbert, Tim Friede & Jan Beyersmann. (2021) Estimating and comparing adverse event probabilities in the presence of varying follow‐up times and competing events. Pharmaceutical Statistics 20:6, pages 1125-1146.
Crossref
Crossref
Regina Stegherr, Jan Beyersmann, Valentine Jehl, Kaspar Rufibach, Friedhelm Leverkus, Claudia Schmoor & Tim Friede. (2020) Survival analysis for AdVerse events with VarYing follow‐up times (SAVVY): Rationale and statistical concept of a meta‐analytic study. Biometrical Journal 63:3, pages 650-670.
Crossref
Crossref
Rachel Phillips, Odile Sauzet & Victoria Cornelius. (2020) Statistical methods for the analysis of adverse event data in randomised controlled trials: a scoping review and taxonomy. BMC Medical Research Methodology 20:1.
Crossref
Crossref
Karen Cheng, Paul Newell, Joseph W. Chow, Helen Broadhurst, David Wilson, Katrina Yates & Angela Wardman. (2020) Safety Profile of Ceftazidime–Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme. Drug Safety 43:8, pages 751-766.
Crossref
Crossref
Ramona Meister, Jana Lanio, Thomas Fangmeier, Martin Härter, Elisabeth Schramm, Ingo Zobel, Martin Hautzinger, Yvonne Nestoriuc & Levente Kriston. (2019) Adverse events during a disorder‐specific psychotherapy compared to a nonspecific psychotherapy in patients with chronic depression. Journal of Clinical Psychology 76:1, pages 7-19.
Crossref
Crossref
Ralf Bender & Lars Beckmann. (2019) Limitations of the incidence density ratio as approximation of the hazard ratio. Trials 20:1.
Crossref
Crossref
Steffen Unkel, Marjan Amiri, Norbert Benda, Jan Beyersmann, Dietrich Knoerzer, Katrin Kupas, Frank Langer, Friedhelm Leverkus, Anja Loos, Claudia Ose, Tanja Proctor, Claudia Schmoor, Carsten Schwenke, Guido Skipka, Kristina Unnebrink, Florian Voss & Tim Friede. (2018) On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies. Pharmaceutical Statistics 18:2, pages 166-183.
Crossref
Crossref
Jacqueline C. Barrientos, Susan O’Brien, Jennifer R. Brown, Neil E. Kay, Nishitha M. Reddy, Steven Coutre, Constantine Tam, Stephen Mulligan, Ulrich Jaeger, Stephen Devereux, Christopher Pocock, Tadeusz Robak, Stephen J. Schuster, Anna Schuh, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Gavin Cull, Mike Hamblin, Jeffrey A. Jones, Karl Eckert, Isabelle G. Solman, Samuel Suzuki, Emily Hsu, Danelle F. James, John C. Byrd & Peter Hillmen. (2018) Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:12, pages 803-813.e7.
Crossref
Crossref
Anthony S. SteinRichard A. LarsonAndre C. SchuhWilliam StevensonEwa Lech-MarandaQui Tran, Zachary Zimmerman, William Kormany & Max S. Topp. (2018) Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Advances 2:13, pages 1522-1531.
Crossref
Crossref
Melvin S. Munsaka. 2018. Biopharmaceutical Applied Statistics Symposium. Biopharmaceutical Applied Statistics Symposium
193
216
.
Jan Beyersmann & Christine Schrade. (2017) Florence Nightingale, William Farr and Competing Risks. Journal of the Royal Statistical Society Series A: Statistics in Society 180:1, pages 285-293.
Crossref
Crossref
Tanja Proctor & Martin Schumacher. (2016) Analysing adverse events by time-to-event models: the CLEOPATRA study. Pharmaceutical Statistics 15:4, pages 306-314.
Crossref
Crossref
Johannes Hengelbrock, Johanna Gillhaus, Sebastian Kloss & Friedhelm Leverkus. (2016) Safety data from randomized controlled trials: applying models for recurrent events. Pharmaceutical Statistics 15:4, pages 315-323.
Crossref
Crossref
Ralf Bender, Lars Beckmann & Stefan Lange. (2016) Biometrical issues in the analysis of adverse events within the benefit assessment of drugs. Pharmaceutical Statistics 15:4, pages 292-296.
Crossref
Crossref
Josef S. Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, Vibeke Strand, Jiri Vencovsky, Michael Schiff, Robert Landewé, Boulos Haraoui, Catherine Arendt, Irina Mountian, David Carter & Désirée van der Heijde. (2015) Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Research & Therapy 17:1.
Crossref
Crossref
Gloria Sanclemente, Ruth Murphy, Javier Contreras, Hermenegildo García & Xavier Bonfill Cosp. (2015) Anti-TNF agents for paediatric psoriasis. Cochrane Database of Systematic Reviews 2019:5.
Crossref
Crossref
Haijun Ma, Chunlei Ke, Qi Jiang & Steven Snapinn. (2015) Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials. Therapeutic Innovation & Regulatory Science 49:6, pages 957-965.
Crossref
Crossref
Ying Zhou, Chunlei Ke, Qi Jiang, Seta Shahin & Steven Snapinn. (2015) Choosing Appropriate Metrics to Evaluate Adverse Events in Safety Evaluation. Therapeutic Innovation & Regulatory Science 49:3, pages 398-404.
Crossref
Crossref
Liqun Diao, Richard J. Cook & Ker-Ai Lee. 2014. Statistical Methods for Evaluating Safety in Medical Product Development. Statistical Methods for Evaluating Safety in Medical Product Development
180
192
.
Subhash Banerjee, Mazen Abu Fadel, Ravi Sarode, Lance Terada, Thomas Moritz, Ping Luo, Jeffrey Hastings, Emmanouil S. Brilakis & Domenic Reda. (2014) Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design. Journal of Clinical Apheresis 29:2, pages 97-106.
Crossref
Crossref
Jixian Wang & George Quartey. (2013) A semi-parametric approach to analysis of event duration and prevalence. Computational Statistics & Data Analysis 67, pages 248-257.
Crossref
Crossref
G. Frank Liu. 2013. Topics in Applied Statistics. Topics in Applied Statistics
273
282
.
Jixian Wang & George Quartey. (2012) Nonparametric estimation for cumulative duration of adverse events. Biometrical Journal 54:1, pages 61-74.
Crossref
Crossref